Compugen Ltd.

Ladies and gentlemen, thank you for joining us today. Welcome to CompuGen's third quarter 2022 results conference call. At this time, all participants are in the listen-only mode. An audio webcast of this call is available in the investors section of CompuGen's website, www.cgen.com. As a reminder, today's call is being recorded. I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.

Thank you, Yanni, and thank you all for joining us on the call today. Joining me from Compogen are Dr. Anako Undayak, President and Chief Executive Officer, Dr. Henry Adewoye, Chief Medical Officer, Dr. Iran Ofer, Senior Vice President, Research and Drug Discovery, and Alberto Sessa, Chief Financial Officer. Before we begin, we would like to remind you that during this call, The company may make projections or forward-looking statements regarding future events, business outlook, development efforts and their potential outcome, the company's discovery platform, anticipated progress and plans, results and timelines for our programs, financial and accounting-related matters, as well as statements regarding our cash business. We wish to caution you that such statements reflect only the company's current beliefs, expectations and assumptions, but actual results, performance or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties, and we refer you to the SEC filings for more details on these risks, including the company's most recent annual report on Form 20F filed with the SEC on February 28, 2022. The company undertakes no obligation to update projections and forward-looking statements in the future. With that, I now turn over to Anat.

Thank you, Yvonne. Good morning and good afternoon, everyone. And welcome to our third quarter 2022 update, fresh after a great CITSE conference in Boston last week, where we had two oral presentations. In the first nine months of the year, we've continued to execute and meet our guidance. We presented clinical data from the MSS CRC expansion cohort at CITSE last week. And in three weeks' time, we will present clinical data from the two ovarian expansion cohorts at ESMO-IO. During our first oral presentation at SIFI, Dr. Michael Overman from MD Anderson presented encouraging overall response rates following treatment with COM701 in combination with nivolumab in heavily pretreated metastatic MSS-CSC patients, a hard-to-treat tumor type, typically not responsive to immunotherapy. Over 70% of the patients from this study had liver metastasis, typical of this patient population who are resistant to treatment. Responses in these patients with liver mets is a key differentiator for COM701 and a unique achievement. On the safety side, there were no serious adverse events deemed by the investigator as related to study drugs. During our oral presentation at CITSE, Eran presented data showing that COM701 in combination with nivolumab results in potent immune modulation in the two MSS-CRC patients with liver mets who responded to treatment, suggesting that the clinical responses we observed in such a cold tumor type are linked to a COM701-mediated effect. He also presented data showing immune modulation in platinum-resistant ovarian cancer patients treated with COM701 monotherapy. This data in an additional cold tumor type, typically not responsive to immunotherapy, is further supported by encouraging data in platinum-resistant ovarian patients treated with dual and triple combination therapy, blocking PDR-IG, and PD-1 with and without blocking TIGIT. We're looking forward to presenting this data at ESMO IO in December. I'm excited that the totality of our data suggests a COM701-mediated effect, and this is specifically encouraging as it is observed in hard-to-treat, non-responsive tumor types. The combination of our translational data from patients' tumor samples along with our preclinical and clinical data suggest that the increased infiltration of T cells to the tumor microenvironment following blockade of PVRIG may be needed to sensitize the tumors to TGIT and PD-1 blockade. We believe that a triple blockade of the denim axis unleashing the three pathways may result in turning cold tumors like MSS-CRC and platinum-resistant ovarian cancer more responsive to such immune checkpoint inhibitors. As a result, we're planning a triple combination study in MSS-CRC patients with our own potential first-in-class COM701 in combination with our own potential best-in-class anti-TGIT COM902 and an anti-PD-1. Our anti-TGIT COM902 was engineered to reduce FP functionality with the potential to enhance anti-tumor activity, and we believe this is the optimal design to pursue clinically and look forward to seeing how this plays out in the clinic. This is further supported by by the preclinical data AstraZeneca recently presented at SITC on their PD1-TG bispecific derived from COM902, also engineered to have reduced the FC function. Moving to ovarian cancer, we believe the encouraging data in platinum-resistant ovarian cancer merits further development in this indication, which opens the door for us in a much less crowded, competitive landscape compared to non-small cell and cancer. For this reason, we have decided to pursue platinum-resistant ovarian cancer, and we're now evaluating the various options for the planned non-small cell and cancer studies. Following the disclosure of the data from the two ovarian cancer studies at ESMO-IO, we will host an investor call to describe the totality of our data and provide details on our studies. We have a solid balance sheet with cash expected to support operations at least through the end of 2024, and we're committed to this guidance and our focus on two indications with what we believe has the highest probability of success. On that note, I would like to welcome on board our new Chief Financial Officer, Alberto Cessa, who is with us today for his first conference call with Compugen. I'm delighted to have Alberto as part of my management team and as we continue to focus on execution and delivering meaningful clinical data and value to our stakeholders. During today's call, Henry will start by providing an overview of the MSS CRC data presented at CITI. Eran will then provide an overview of the research and translational data that he presented at CITI. I will then set the expectations ahead of the data in platinum-resistant ovarian cancer patients, which we will present at ESMO-IO. Alberto will then bring you through the third quarter financials, and then we will open the call for questions. With that, I will hand over to Henry.